<DOC>
	<DOCNO>NCT00963495</DOCNO>
	<brief_summary>This open-label , single arm phase 1 study evaluate dose-limiting toxicity , maximum tolerate dose , recommend phase II dose Clioquinol patient relapse refractory hematologic malignancy . The study also characterize Cliquinol 's safety , tolerability pharmacodynamic effect .</brief_summary>
	<brief_title>Study Evaluating Tolerance Biological Activity Oral Clioquinol Patients With Relapsed Refractory Hematological Malignancy</brief_title>
	<detailed_description>This open-label , single arm study . Approximately 4-48 patient enrol . Patients receive 800mg/day Clioquinol start trial dose increase 800mg subsequent level MTD determine . Patients increase frequency drug . Response Clioquinol determine day 21 8 15 day dose schedule day 28 22 day dose schedule ( 1 cycle ) . Patients demonstrated response drug eligible receive 5 additional cycle dose frequency every 21 day .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<criteria>1 . Relapsed refractory acute myeloid leukemia ( AML ) , acute lymphocytic leukemia ( ALL ) , chronic lymphocytic leukemia ( CLL ) , high risk myelodysplasia ( MDS ) IPSS score &gt; 2.5 , NonHodgkin 's lymphoma ( NHL ) , Hodgkin 's lymphoma ( HD ) multiple myeloma , potentially curative standard salvage therapy option exhaust . 2 . ECOG performance status &lt; 2 . 3 . Biochemical value within follow range : Serum creatinine &lt; 2x upper limit normal . Total bilirubin &lt; 2x upper limit normal , AST ALT &lt; 5x upper limit normal . Normal serum B12 level . 4 . Ability maintain adequate oral intake medication . 5 . Ability understand sign inform consent . 6 . Toxicity prior chemotherapy resolve . 1 . Uncontrolled systemic infection . 2 . Uncontrolled intracurrent illness . 3 . Pregnant breast feeding . 4 . CNS disease . 5 . Neurologic symptom related intracurrent illness unexplained cause . 6 . Psychiatric illness would limit compliance study . 7 . Receiving systemic chemotherapy , hydroxyurea control circulate blast count , within 10 day study entry . Hydroxyurea permit , however dose must stable unchanged 7 day prior initiation Clioquinol . 8 . Prior therapy Clioquinol . 9 . Use investigational antileukemic therapy within two week study entry . 10 . Given neurological side Clioquinol Japanese population , population , trial exclude patient parent Oriental Japanese origin selfidentify Oriental Japanese ( Appendix 9.2 ) . 11 . Active ocular problem include visual migraine glaucoma . 12 . Use oral intravenous heavy metal supplement include copper , zinc , nickel .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>clioquinol</keyword>
	<keyword>relapsed refractory hematologic malignancy</keyword>
	<keyword>ALL</keyword>
	<keyword>HD</keyword>
	<keyword>CLL</keyword>
	<keyword>High risk myelodysplasia ( MDS ) IPSS score &gt; 2.5</keyword>
	<keyword>CML blast crisis</keyword>
	<keyword>Relapsed refractory acute myeloid leukemia ( AML )</keyword>
</DOC>